{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126787","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.640743+00:00","generated_at":"2026-05-30T00:26:11.227993+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k","bullets":["Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.","Gross margin improved to 46.0% from 45.1% YoY; operating loss narrowed to $0.3M from $0.4M.","Adjusted EBITDA loss of $75k, near breakeven versus $0.4M loss a year ago.","Cash balance $1.0M at quarter end; secured $0.9M net proceeds from Streeterville financing.","Launched +PlusHLTH supplement line (CLARITY, PEACE, RESHAPE) and new pet chews."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126787","json":"https://secwatch.observer/filing/0000950170-24-126787.json","markdown":"https://secwatch.observer/filing/0000950170-24-126787.md","text":"https://secwatch.observer/filing/0000950170-24-126787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/0000950170-24-126787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017024126787/cvsi-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:26:11.227993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}